$109.61
0.78[0.72%]
Last update: 9:30AM Get Real Time Here
Jazz Pharmaceuticals
(NASDAQ:JAZZ)Jazz Pharmaceuticals Stock (NASDAQ:JAZZ), Analyst Ratings, Price Targets, Predictions
Jazz Pharmaceuticals PLC has a consensus price target of $185.16, established from looking at the 66 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, JP Morgan, and Cantor Fitzgerald on April 10, 2024, March 22, 2024, and March 22, 2024. With an average price target of $183.33 between Cantor Fitzgerald, JP Morgan, and Cantor Fitzgerald, there's an implied 67.26% upside for Jazz Pharmaceuticals PLC from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
JP Morgan
Truist Securities
Piper Sandler
Needham
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Jazz Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 64.22% | Cantor Fitzgerald | Charles Duncan | → $180 | Reiterates | Overweight → Overweight | Get Alert |
| 03/22/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 73.34% | JP Morgan | Jessica Fye | $170 → $190 | Maintains | Overweight | Get Alert |
| 03/22/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 64.22% | Cantor Fitzgerald | Charles Duncan | → $180 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 82.47% | Truist Securities | Joon Lee | → $200 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 71.52% | Piper Sandler | David Amsellem | $171 → $188 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 100.71% | Needham | Ami Fadia | → $220 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 109.83% | Stifel | Annabel Samimy | $225 → $230 | Maintains | Buy | Get Alert |
| 03/14/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 82.47% | HC Wainwright & Co. | Oren Livnat | $204 → $200 | Maintains | Buy | Get Alert |
| 03/01/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 109.83% | Barclays | Balaji Prasad | $235 → $230 | Maintains | Overweight | Get Alert |
| 03/01/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 19.51% | UBS | Ashwani Verma | $135 → $131 | Maintains | Neutral | Get Alert |
| 02/29/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 64.22% | Cantor Fitzgerald | Charles Duncan | → $180 | Reiterates | Overweight → Overweight | Get Alert |
| 02/29/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 77.9% | RBC Capital | Gregory Renza | → $195 | Reiterates | Outperform → Outperform | Get Alert |
| 02/29/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 55.1% | JP Morgan | Jessica Fye | $180 → $170 | Maintains | Overweight | Get Alert |
| 02/29/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 100.71% | Needham | Ami Fadia | $225 → $220 | Maintains | Buy | Get Alert |
| 01/29/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 114.4% | Barclays | Balaji Prasad | $240 → $235 | Maintains | Overweight | Get Alert |
| 01/03/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 45.97% | Baird | Joel Beatty | → $160 | Initiates | → Outperform | Get Alert |
| 12/04/2023 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 82.47% | Truist Securities | Joon Lee | → $200 | Reiterates | Buy → Buy | Get Alert |
| 11/29/2023 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 105.27% | Needham | Ami Fadia | → $225 | Reiterates | Buy → Buy | Get Alert |
| 11/27/2023 | JAZZ | Buy Now | Jazz Pharmaceuticals | $109.61 | 23.16% | UBS | Ashwani Verma | $170 → $135 | Downgrade | Buy → Neutral | Get Alert |
FAQ
What is the target price for Jazz Pharmaceuticals (JAZZ)?
The latest price target for Jazz Pharmaceuticals (NASDAQ: JAZZ) was reported by Cantor Fitzgerald on April 10, 2024. The analyst firm set a price target for $180.00 expecting JAZZ to rise to within 12 months (a possible 64.22% upside). 36 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Jazz Pharmaceuticals (JAZZ)?
The latest analyst rating for Jazz Pharmaceuticals (NASDAQ: JAZZ) was provided by Cantor Fitzgerald, and Jazz Pharmaceuticals reiterated their overweight rating.
When was the last upgrade for Jazz Pharmaceuticals (JAZZ)?
The last upgrade for Jazz Pharmaceuticals PLC happened on December 9, 2022 when Goldman Sachs raised their price target to $190. Goldman Sachs previously had a neutral for Jazz Pharmaceuticals PLC.
When was the last downgrade for Jazz Pharmaceuticals (JAZZ)?
The last downgrade for Jazz Pharmaceuticals PLC happened on November 27, 2023 when UBS changed their price target from $170 to $135 for Jazz Pharmaceuticals PLC.
When is the next analyst rating going to be posted or updated for Jazz Pharmaceuticals (JAZZ)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jazz Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jazz Pharmaceuticals was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating Jazz Pharmaceuticals (JAZZ) correct?
While ratings are subjective and will change, the latest Jazz Pharmaceuticals (JAZZ) rating was a reiterated with a price target of $0.00 to $180.00. The current price Jazz Pharmaceuticals (JAZZ) is trading at is $109.61, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.